ATOSSA THERAPEUTICS INC
ATOSNASDAQTrading Snapshot
- Day Range
- $1.97 β $2.02
- 52-Week Range
- $1.70 β $19.35
- Volume
- $1.89B
- Avg Volume
- $1.54B
- Shares Outstanding
- 10.0M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $446,511
- P/E Ratio
- -0.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.0%
Why Investors Own ATOS
- βHigh-growth profile β revenue up +8.9% YoY with expanding US Equity exposure.
- βHealthy economics β 38% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ATOSSA THERAPEUTICS INC
ATOS
StockOtter Β· stockotter.spaceAbout ATOSSA THERAPEUTICS INC
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review vouc
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa"
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clin
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE, July 28, 2026 /PRNe
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-Ξ²/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 21, 2026 /PRNewswire/